SCHEMBL6868528

SCHEMBL6868528

COc1cc(-c2cn([C@H]3CC[C@@H](N4CCN(C)CC4)CC3)c3ncnc(N)c23)ccc1N

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TEK Q02763 4/20 0.70
SRC P12931 9/20 0.67
EGFR P00533 6/20 0.67
ABL1 P00519 5/20 0.67
LCK P06239 4/20 0.67
KDR P35968 4/20 0.67
RET P07949 3/20 0.67
HCK P08631 3/20 0.67
PAK4 O96013 2/20 0.67
CHEK2 O96017 2/20 0.67
INSR P06213 2/20 0.67
CSF1R P07333 2/20 0.67
LYN P07948 2/20 0.67
FGFR1 P11362 2/20 0.67
RPS6KB1 P23443 2/20 0.67
MARK3 P27448 2/20 0.67
FLT4 P35916 2/20 0.67
FLT3 P36888 2/20 0.67
CSNK1D P48730 2/20 0.67
BLK P51451 2/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6467070 1.00 TEK (0.70) TEKSRCEGFRABL1LCK
SCHEMBL6467066 1.00 TEK (0.70) TEKSRCEGFRABL1LCK
SCHEMBL23966915 0.91 RIPK2 (0.67) TEKSRCEGFRABL1LCK
SCHEMBL30180912 0.91 RIPK2 (0.67) TEKSRCEGFRABL1LCK
SCHEMBL2072160 0.87 SRC (0.73) TEKSRCEGFRABL1LCK
SCHEMBL6109524 0.87 RIPK2 (0.75) TEKSRCEGFRABL1LCK
SCHEMBL6461133 0.87 RIPK2 (0.75) TEKSRCEGFRABL1LCK
SCHEMBL6109525 0.87 RIPK2 (0.75) TEKSRCEGFRABL1LCK
SCHEMBL6460212 0.86 TEK (0.74) TEKSRCEGFRABL1LCK
SCHEMBL6865257 0.85 SRC (0.63) TEKSRCEGFRABL1LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6713474-B2 SERINE-THREONINE AND TYROSINE KINASE INHIBITORS ABBOTT GMBH & CO. KG (DE) 2004-03-30 US disclosed
US-20030153752-A1 Pyrrolopyrimidines as therapeutic agents ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2003-08-14 US disclosed
EP-1114053-A1 PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS BASF AKTIENGESELLSCHAFT (DE) 2001-07-11 EP disclosed
WO-2000017203-A1 PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS BASF AKTIENGESELLSCHAFT (DE) 2000-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030153752-A1 Pyrrolopyrimidines as therapeutic agents FLT1, FLT4, TFPI TEK 22/4885SRC 206/4885EGFR 457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.